Peptora Get app
← All peptides

CagriSema

★ 80

Cagrilintide + Semaglutide combination

Powerful semaglutide + cagrilintide combination

Fat Loss
Half-life
~1 week (both components)
Route
Subcutaneous (SubQ)
Cycle
Long-term maintenance, same
Status
Phase 3 (REDEFINE program)

About

Novo Nordisk's Phase 3 combination of cagrilintide (long-acting amylin analog) and semaglutide. Aimed at exceeding tirzepatide for weight loss.

Mechanism

Dual action: cagrilintide reduces appetite via amylin receptors, semaglutide activates GLP-1.

Dosage

beginner

Amount
0.25 mg + 0.25 mg
Frequency
1x per week (4-week titration)
Route
Subcutaneous (SubQ)
Duration
Long-term

standard

Amount
1.0 mg + 1.0 mg
Frequency
1x per week
Route
Subcutaneous (SubQ)
Duration
Long-term

advanced

Amount
2.4 mg + 2.4 mg
Frequency
1x per week (max)
Route
Subcutaneous (SubQ)
Duration
Long-term
Timing

Same weekday each week. Best in the morning or evening.

Cycle structure

Long-term maintenance, same pattern as semaglutide.

Reconstitution & Storage

5 mg + 5 mg + 2 mL → 2.5 mg/mL each

The clinical form is a pre-mixed pen. Compounded forms are blended together.

Lyophilized: refrigerated 2-8°C. After reconstitution: 2-8°C, 28 days.

Benefits

  • • Potentially largest weight loss among GLP-1 drugs
  • • Smoother appetite control (dual mechanism)
  • • Improved glycemic control
  • • Less nausea than pure semaglutide

Side effects

  • • Nausea and vomiting (common initially)
  • • Diarrhea or constipation
  • • Headache
  • • Possible pancreatitis (rare)

Contraindications

  • • Pregnancy and breastfeeding
  • • History of pancreatitis
  • • Medullary thyroid carcinoma (MEN2)
  • • Severe gastroparesis

Gender notes

Men

Same dose as general protocol.

Women

Same dose. Check fertility plans before starting.

Research

Stacks well with

MOTS-C TESAMORELIN

Track CagriSema doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.